Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours
| dc.contributor.author | Zurita, A. J. | |
| dc.contributor.author | Diestra, J. E. | |
| dc.contributor.author | Condom i Mundó, Enric | |
| dc.contributor.author | García del Muro Solans, Xavier | |
| dc.contributor.author | Scheffer, G. L. | |
| dc.contributor.author | Scheper, R. J. | |
| dc.contributor.author | Pérez, J. | |
| dc.contributor.author | Germà Lluch, José Ramón | |
| dc.contributor.author | Izquierdo, M. A. | |
| dc.date.accessioned | 2018-03-13T10:54:50Z | |
| dc.date.available | 2018-03-13T10:54:50Z | |
| dc.date.issued | 2003-03-24 | |
| dc.date.updated | 2018-03-13T10:54:50Z | |
| dc.description.abstract | This study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp), 54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP (P=0.026) and high LDH levels (P=0.014), whereas LRP expression associated with high β-hCG levels (P=0.003) and stage IV tumours (P=0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free (P=0.0006) and overall survival (P=0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated with an adverse clinical outcome. | |
| dc.format.extent | 8 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 524876 | |
| dc.identifier.issn | 0007-0920 | |
| dc.identifier.pmid | 12644825 | |
| dc.identifier.uri | https://hdl.handle.net/2445/120651 | |
| dc.language.iso | eng | |
| dc.publisher | Cancer Research UK | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/sj.bjc.6600803 | |
| dc.relation.ispartof | British Journal of Cancer, 2003, vol. 88, num. 6, p. 879-886 | |
| dc.relation.uri | https://doi.org/10.1038/sj.bjc.6600803 | |
| dc.rights | cc-by-nc-sa (c) Zurita, A. J. et al., 2003 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/es | |
| dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | |
| dc.subject.classification | Malalties del testicle | |
| dc.subject.classification | Cèl·lules germinals | |
| dc.subject.classification | Tumors | |
| dc.subject.classification | Expressió gènica | |
| dc.subject.classification | Proteïnes supressores de tumors | |
| dc.subject.classification | Resistència als medicaments | |
| dc.subject.other | Testis diseases | |
| dc.subject.other | Germ cells | |
| dc.subject.other | Tumors | |
| dc.subject.other | Gene expression | |
| dc.subject.other | Tumor suppressor protein | |
| dc.subject.other | Drug resistance | |
| dc.title | Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1